Literature DB >> 18535118

Low tidal volume ventilation is associated with reduced mortality in HIV-infected patients with acute lung injury.

J L Davis1, A Morris, R H Kallet, K Powell, A S Chi, M Bensley, J M Luce, L Huang.   

Abstract

BACKGROUND: Respiratory failure remains the leading indication for admission to the intensive care unit (ICU) and a leading cause of death for HIV-infected patients in spite of overall improvements in ICU mortality. It is unclear if these improvements are due to combination anti-retroviral therapy, low tidal volume ventilation for acute lung injury, or both. A study was undertaken to identify therapies and clinical factors associated with mortality in acute lung injury among HIV-infected patients with respiratory failure in the period 1996-2004. A secondary aim was to compare mortality before and after introduction of a low tidal volume ventilation protocol in 2000.
METHODS: A retrospective cohort study was performed of 148 consecutive HIV-infected adults admitted to the ICU at San Francisco General Hospital with acute lung injury requiring mechanical ventilation. Demographic and clinical information including data on mechanical ventilation was abstracted from medical records and analysed by multivariate analysis using logistic regression.
RESULTS: In-hospital mortality was similar before and after introduction of a low tidal volume ventilation protocol, although the study was not powered to exclude a clinically significant difference (risk difference -5.4%, 95% CI -21% to 11%, p = 0.51). Combination antiretroviral therapy was not clearly associated with mortality, except in patients with Pneumocystis pneumonia. Among all those with acute lung injury, lower tidal volume was associated with decreased mortality (adjusted odds ratio 0.76 per 1 ml/kg decrease, 95% CI 0.58 to 0.99, p = 0.043), after controlling for Pneumocystis pneumonia, serum albumin, illness severity, gas exchange impairment and plateau pressure.
CONCLUSIONS: Lower tidal volume ventilation is independently associated with reduced mortality in HIV-infected patients with acute lung injury and respiratory failure.

Entities:  

Mesh:

Year:  2008        PMID: 18535118      PMCID: PMC2677080          DOI: 10.1136/thx.2008.095786

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  34 in total

1.  Outcomes of intensive care for patients with human immunodeficiency virus infection.

Authors:  G Nickas; R M Wachter
Journal:  Arch Intern Med       Date:  2000-02-28

2.  In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii.

Authors:  C Atzori; E Angeli; A Mainini; F Agostoni; V Micheli; A Cargnel
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

3.  Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome.

Authors:  Thomas J Nuckton; James A Alonso; Richard H Kallet; Brian M Daniel; Jean-François Pittet; Mark D Eisner; Michael A Matthay
Journal:  N Engl J Med       Date:  2002-04-25       Impact factor: 91.245

4.  Detection of patient-ventilator asynchrony during low tidal volume ventilation, using ventilator waveform graphics.

Authors:  Richard H Kallet; John M Luce
Journal:  Respir Care       Date:  2002-02       Impact factor: 2.258

Review 5.  Physiologic rationale for ventilator setting in acute lung injury/acute respiratory distress syndrome patients.

Authors:  Luciano Gattinoni; Federica Vagginelli; Davide Chiumello; Paolo Taccone; Eleonora Carlesso
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

6.  Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia.

Authors:  Alison Morris; Robert M Wachter; John Luce; Joan Turner; Laurence Huang
Journal:  AIDS       Date:  2003-01-03       Impact factor: 4.177

7.  Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit.

Authors:  Enrique Casalino; Michel Wolff; Philippe Ravaud; Christophe Choquet; Fabrice Bruneel; Bernard Regnier
Journal:  AIDS       Date:  2004-07-02       Impact factor: 4.177

8.  Intensive care in patients with HIV infection in the era of highly active antiretroviral therapy.

Authors:  Mangala Narasimhan; Adam J Posner; Vera A DePalo; Paul H Mayo; Mark J Rosen
Journal:  Chest       Date:  2004-05       Impact factor: 9.410

9.  Acute respiratory distress syndrome caused by pulmonary and extrapulmonary disease. Different syndromes?

Authors:  L Gattinoni; P Pelosi; P M Suter; A Pedoto; P Vercesi; A Lissoni
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

10.  Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy.

Authors:  Alison Morris; Jennifer Creasman; Joan Turner; John M Luce; Robert M Wachter; Laurence Huang
Journal:  Am J Respir Crit Care Med       Date:  2002-08-01       Impact factor: 21.405

View more
  12 in total

1.  Outcomes for critically ill patients with HIV and severe sepsis in the era of highly active antiretroviral therapy.

Authors:  Jared A Greenberg; Jeffrey L Lennox; Greg S Martin
Journal:  J Crit Care       Date:  2011-10-26       Impact factor: 3.425

Review 2.  Critical illness in HIV-infected patients in the era of combination antiretroviral therapy.

Authors:  Kathleen M Akgün; Laurence Huang; Alison Morris; Amy C Justice; Margaret Pisani; Kristina Crothers
Journal:  Proc Am Thorac Soc       Date:  2011-06

Review 3.  An official ATS workshop report: Emerging issues and current controversies in HIV-associated pulmonary diseases.

Authors:  Alison Morris; Kristina Crothers; James M Beck; Laurence Huang
Journal:  Proc Am Thorac Soc       Date:  2011-03

4.  Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients.

Authors:  André M Japiassú; Rodrigo T Amâncio; Emerson C Mesquita; Denise M Medeiros; Helena B Bernal; Estevão P Nunes; Paula M Luz; Beatriz Grinsztejn; Fernando A Bozza
Journal:  Crit Care       Date:  2010-08-10       Impact factor: 9.097

5.  Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.

Authors:  Jannik Helweg-Larsen; Thomas Benfield; Chiara Atzori; Robert F Miller
Journal:  J Antimicrob Chemother       Date:  2009-10-26       Impact factor: 5.790

6.  Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study.

Authors:  M W Fei; E J Kim; C A Sant; L G Jarlsberg; J L Davis; A Swartzman; L Huang
Journal:  Thorax       Date:  2009-10-12       Impact factor: 9.139

7.  Should highly active antiretroviral therapy be prescribed in critically ill HIV-infected patients during the ICU stay? A retrospective cohort study.

Authors:  Agnes Meybeck; Lydie Lecomte; Michel Valette; Nicolas Van Grunderbeeck; Nicolas Boussekey; Arnaud Chiche; Hugues Georges; Yazdan Yazdanpanah; Olivier Leroy
Journal:  AIDS Res Ther       Date:  2012-09-28       Impact factor: 2.250

Review 8.  Clinical review: Respiratory failure in HIV-infected patients--a changing picture.

Authors:  Putul Sarkar; Husham F Rasheed
Journal:  Crit Care       Date:  2013-06-14       Impact factor: 9.097

9.  The ART of caring for patients with HIV infection in the ICU.

Authors:  Krista Powell; Laurence Huang
Journal:  Intensive Care Med       Date:  2009-07-28       Impact factor: 17.440

10.  Impact of intraoperative lung-protective interventions in patients undergoing lung cancer surgery.

Authors:  Marc Licker; John Diaper; Yann Villiger; Anastase Spiliopoulos; Virginie Licker; John Robert; Jean-Marie Tschopp
Journal:  Crit Care       Date:  2009-03-24       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.